文献速递产科母胎医学

COVID-19相关急性呼吸窘迫综合征孕妇择期分娩与期待治疗的临床决策分析

Clinical decision analysis of elective delivery vs expectant management for pregnant individuals with COVID-19-related acute respiratory distress syndrome.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-07-22

本研究采用患者水平模型模拟32周妊娠、因COVID-19相关急性呼吸窘迫综合征有创通气的孕妇,比较择期剖宫产与期待治疗对母婴质量调整预期寿命的影响。结果显示孕妇结局相似,新生儿在择期分娩时围产期生存率和质量调整预期寿命更高。结论建议根据孕龄、宫内死亡风险及孕妇急性呼吸窘迫综合征严重程度决定分娩时机。

要点

  • 对孕妇,择期分娩与期待治疗在28至34周孕龄间结局相当,择期分娩未优于期待治疗。
  • 对新生儿,孕龄≥30周或宫内死亡/孕妇死亡风险高时,择期分娩质量调整预期寿命更高。
  • 决策应基于孕龄、宫内死亡可能性及孕妇急性呼吸窘迫综合征严重程度。

核心结论

  • 对COVID-19相关急性呼吸窘迫综合征孕妇,择期分娩与期待治疗的选择应基于孕龄、宫内死亡风险和孕妇急性呼吸窘迫综合征严重程度。
  • 对孕妇,孕龄28至34周时择期分娩与期待治疗相当但未优于期待治疗。
  • 对新生儿,孕龄≥30周且宫内死亡或孕妇死亡风险高时择期分娩更优。

研究设计与样本

  • 采用患者水平模型进行临床决策分析,模拟32周妊娠、因COVID-19相关急性呼吸窘迫综合征有创通气的孕妇及其胎儿。
  • 模型采用平行开放队列结构、日周期长度、连续贴现、终身时间跨度,对关键参数进行敏感性分析,并迭代1000次量化不确定性。
  • 择期分娩策略为立即剖宫产,期待治疗策略为继续妊娠直至自然临产或产科决定分娩。

主要发现

  • 孕妇结局:择期分娩组医院生存率87.1% vs 期待治疗组87.4%,生命年差异-0.1(95%可信区间-1.4至1.1),质量调整预期寿命差异-0.1年(95%可信区间-1.3至1.1)。
  • 新生儿结局:择期分娩组围产期生存率98.4% vs 期待治疗组93.2%,差异5.2%(95%可信区间3.5-7);生命年差异0.9(95%可信区间-0.9至2.8);质量调整预期寿命差异1.3年(95%可信区间0.4-2.2)。
  • 孕龄30周时择期分娩新生儿质量调整预期寿命差异1.1年(95%可信区间0.1-2.1),但长期并发症更高(4.3% vs 0.5%;差异3.7%;95%可信区间2.4-5.1)。
  • 在宫内死亡或孕妇死亡可能性更高的情况下,择期分娩获得更高的新生儿质量调整预期寿命。

关键数值与推荐

  • 孕妇医院生存率:择期分娩87.1% vs 期待治疗87.4%。
  • 新生儿围产期生存率:择期分娩98.4% vs 期待治疗93.2%,差异5.2%(95%可信区间3.5-7)。
  • 新生儿质量调整预期寿命差异:1.3年(95%可信区间0.4-2.2),利于择期分娩。
  • 孕龄30周择期分娩新生儿质量调整预期寿命差异:1.1年(95%可信区间0.1-2.1),长期并发症4.3% vs 0.5%(差异3.7%;95%可信区间2.4-5.1)。

临床怎么用

  • 作者建议基于孕龄和宫内或孕妇死亡可能性来决定COVID-19相关急性呼吸窘迫综合征孕妇是否择期分娩。
  • 对孕妇,孕龄28至34周时择期分娩与期待治疗相当但未优于期待治疗。
  • 对新生儿,孕龄≥30周且宫内死亡或孕妇死亡风险高时,择期分娩更优。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant individuals are vulnerable to COVID-19-related acute respiratory distress syndrome. There is a lack of high-quality evidence on whether elective delivery or expectant management leads to better maternal and neonatal outcomes. OBJECTIVE: This study aimed to determine whether elective delivery or expectant management are associated with higher quality-adjusted life expectancy for pregnant individuals with COVID-19-related acute respiratory distress syndrome and their neonates. STUDY DESIGN: We performed a clinical decision analysis using a patient-level model in which we simulatedpregnant individuals and their unborn children. We used a patient-level model with parallel open-cohort structure, daily cycle length, continuous discounting, lifetime horizon, sensitivity analyses for key parameter values, and 1000 iterations for quantification of uncertainty. We simulated pregnant individuals at 32 weeks of gestation, invasively ventilated because of COVID-19-related acute respiratory distress syndrome. In the elective delivery strategy, pregnant individuals received immediate cesarean delivery. In the expectant management strategy, pregnancies continued until spontaneous labor or obstetrical decision to deliver. For both pregnant individuals and neonates, model outputs were hospital or perinatal survival, life expectancy, and quality-adjusted life expectancy denominated in years, summarized by the mean and 95% credible interval. Maternal utilities incorporated neonatal outcomes in accordance with best practices in perinatal decision analysis. RESULTS: Model outputs for pregnant individuals were similar when comparing elective delivery at 32 weeks' gestation with expectant management, including hospital survival (87.1% vs 87.4%), life-years (difference, -0.1; 95% credible interval, -1.4 to 1.1), and quality-adjusted life expectancy denominated in years (difference, -0.1; 95% credible interval, -1.3 to 1.1). For neonates, elective delivery at 32 weeks' gestation was estimated to lead to a higher perinatal survival (98.4% vs 93.2%; difference, 5.2%; 95% credible interval, 3.5-7), similar life-years (difference, 0.9; 95% credible interval, -0.9 to 2.8), and higher quality-adjusted life expectancy denominated in years (difference, 1.3; 95% credible interval, 0.4-2.2). For pregnant individuals, elective delivery was not superior to expectant management across a range of scenarios between 28 and 34 weeks of gestation. Elective delivery in cases where intrauterine death or maternal mortality were more likely resulted in higher neonatal quality-adjusted life expectancy, as did elective delivery at 30 weeks' gestation (difference, 1.1 years; 95% credible interval, 0.1 - 2.1) despite higher long-term complications (4.3% vs 0.5%; difference, 3.7%; 95% credible interval, 2.4-5.1), and in cases where intrauterine death or maternal acute respiratory distress syndrome mortality were more likely. CONCLUSION: The decision to pursue elective delivery vs expectant management in pregnant individuals with COVID-19-related acute respiratory distress syndrome should be guided by gestational age, risk of intrauterine death, and maternal acute respiratory distress syndrome severity. For the pregnant individual, elective delivery is comparable but not superior to expectant management for gestational ages from 28 to 34 weeks. For neonates, elective delivery was superior if gestational age was ≥30 weeks and if the rate of intrauterine death or maternal mortality risk were high. We recommend basing the decision for elective delivery vs expectant management in a pregnant individual with COVID-19-related acute respiratory distress syndrome on gestational age and likelihood of intrauterine or maternal death.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Resende MHF, Yarnell CJ, D'Souza R, et al. Clinical decision analysis of elective delivery vs expectant management for pregnant individuals with COVID-19-related acute respiratory distress syndrome. Am J Obstet Gynecol MFM. 2022. PMID: 35878805. doi:10.1016/j.ajogmf.2022.100697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。